



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/21 (03-03)

Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/617,038
		Filing Date	July 11, 2003
		First Named Inventor	Andersen et al
		Group Art Unit	1614
		Examiner Name	
Total Number of Pages in this Submission	5	Attorney Docket Number	SSI5AUSA

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	15-References
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	HOWSON AND HOWSON Mary E. Bak
Signature	
Date	February 12, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this date:

Typed or printed name	
Signature	
Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1 -800-PTO-9199 (1-800-786-9199) and select option 2.

Express Mail No. EU531575547US

Customer No. 00270



CUSTOMER NO. 00270

SSI5AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit: 1614
Andersen et al)
Appln. No. 10/617,038) Examiner:
Filed: July 11, 2003)
For: THERAPEUTIC TB VACCINE) Confirmation No. 5215
) February 12, 2004

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08B is attached and a copy of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Express Mail No. EU531575547US

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
Phone: (215) 540-9200
Fax: (215) 540-5818

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.



<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/617,038
				Filing Date	July 11, 2003
				First Named Inventor	Andersen et al
				Group Art Unit	1614
Examiner Name					
Sheet	1	of	2	Attorney Docket Number	SSI5AUSA

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column/issue number(s), publisher, city and/or country where published	T ²
	X	COTE-SIERRA ET AL , A New Membrane-bound OprI lipoprotein Expression Vector High Production of Heterologous Fusion Proteins in Gram (-) Bacteria and the Implications for Oral Vaccination, Gene 221 pp. 25-34, (August 10, 1998)	
	Y	GOSSELIN ET AL , Enhanced Antigen Presentation Using Human Fcγ Receptor (Monocyte/Macrophage)-Specific Immunogens, The Journal of Immunology, Vol. 149, No. 11, pp. 3477-3481 (December 1, 1992)	
	Z	HÖNER ZU BENTRUP ET AL , Mycobacterial Persistence: Adaptation to a Changing Environment, Trends in Microbiology, Vol. 9, No. 12, pp. 597-605, (December 2001)	
	AA	KILGUS ET AL , Analysis of the Permissive Association of a Malaria T Cell Epitope with DR Molecules, The Journal of Immunology, Vol. 146, No. 1, pp. 307-315, (January 1, 1991)	
	BB	KOHLER ET AL , Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity, Nature, Vol. 256 (5517):pp. 495-7, (August 7, 1975)	
	CC	LOWRIE ET AL , Therapy of Tuberculosis in Mice By DNA Vaccination, Nature, Vol. 400, pp. 269-271, (July 15, 1999)	
	DD	LUSTIG ET AL , Humoral and Cellular Responses to Native Antigen Following Oral and Parenteral Immunization with Lipid-Conjugated Bovine Serum Albumin, Cellular Immunology, 24, pp. 164-172, (June 1, 1976)	
	EE	MCCAFFERTY ET AL , Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains, Nature Vol. 348, pp. 552-554, (December 6, 1990)	
	FF	MOWAT ET AL , Immune-Stimulating Complexes Containing Quil A and Protein Antigen Prime Class I MHC-restricted T Lymphocytes In Vivo and are Immunogenic by the Oral Route, Immunology, 72, (3), pp. 317-322, (March 1991)	
Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/617,038
				Filing Date	July 11, 2003
				First Named Inventor	Andersen et al
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	SSISUSA

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column/issue number(s), publisher, city and/or country where published	T ²
	GG	NAGAI ET AL, Isolation and Partial Characterization of Major Protein Antigens in the Culture Fluid of Mycobacterium Tuberculosis, Infection and Immunity, Vol. 59, No. 1, pp. 372-382, (January 1991)	
	HH	STRYHN ET AL, Peptide Binding Specificity of Major Histocompatibility Complex. Class I Resolved into an Array of Apparently Independent Subspecificities: Quantitation by Peptide Libraries and Improves Prediction of Binding, Eur. J. Immunol. 26, pp. 1911-1918, (August 1996)	
	II	ROLPH ET AL, Recombinant Viruses as Vaccines and Immunological Tools, Curr. Opin. Immunol. 9, 4, pp. 453-5, (August 1997)	
	JJ	OLSEN ET AL, Efficient Protection Against Mycobacterium Tuberculosis by Vaccination with a Single Subdominant Epitope from the ESAT-6 Antigen, 30, 6, pp. 1724-1732, (June 2000)	
	KK	THOMPSON ET AL, Clustal W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice, Nucleic Acids Research, Vol. 22, No. 22, pp. 4673-4680, (November 11, 1994)	
	LL	VAN PINXTEREN ET AL, Control of Latent Mycobacterium Tuberculosis Infection is Dependent on CD8 T Cells, Eur. J. Immunol. 30, 12, pp. 3689-3698, (December 2000)	
Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.